BC Week In Review | Jul 20, 2018
Company News

U of Helsinki grants Herantis rights to a non-invasive CDNF approach

University of Helsinki (Helsinki, Finland) granted Herantis Pharma plc (HSE:HRTIS) exclusive, worldwide rights to a therapeutic approach for non-invasive delivery of cerebral dopamine neurotrophic factor (CDNF) based on a modification of natural CDNF. The partners...
Items per page:
1 - 1 of 1